Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Enterprise Value (2016 - 2025)

IGC Pharma (IGC) has disclosed Enterprise Value for 16 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value changed N/A to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.1 million, a 485.49% decrease, with the full-year FY2025 number at -$405000.0, up 66.19% from a year prior.
  • Enterprise Value was -$1.1 million for Q3 2025 at IGC Pharma, down from -$454000.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$193000.0 in Q3 2022 to a low of -$13.3 million in Q2 2021.
  • A 5-year average of -$3.7 million and a median of -$2.0 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 1569.43% in 2023, then skyrocketed 75.11% in 2025.
  • IGC Pharma's Enterprise Value stood at -$13.3 million in 2021, then soared by 62.21% to -$5.0 million in 2022, then soared by 35.98% to -$3.2 million in 2023, then surged by 85.41% to -$470000.0 in 2024, then tumbled by 140.43% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Enterprise Value are -$1.1 million (Q3 2025), -$454000.0 (Q2 2025), and -$405000.0 (Q1 2025).